Citigroup
KRYS icon

Citigroup’s Krystal Biotech KRYS Stock Holding History

Citigroup’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.05M Buy
31,172
+1,229
+4% +$327K ﹤0.01% 1607
2025
Q4 		$7.38M Buy
29,943
+20,293
+210% +$4.27M ﹤0.01% 1747
2025
Q3 		$1.7M Sell
9,650
-42,883
-82% -$6.42M ﹤0.01% 2803
2025
Q2 		$7.22M Sell
52,533
-20,992
-29% -$3.08M ﹤0.01% 1609
2025
Q1 		$13.3M Sell
73,525
-26,108
-26% -$4.39M 0.01% 1190
2024
Q4 		$15.6M Buy
99,633
+64,549
+184% +$11.5M 0.01% 1109
2024
Q3 		$6.39M Buy
35,084
+13,874
+65% +$2.68M ﹤0.01% 1649
2024
Q2 		$3.9M Sell
21,210
-30,908
-59% -$5.19M ﹤0.01% 1821
2024
Q1 		$9.27M Buy
52,118
+15,552
+43% +$2.16M 0.01% 1297
2023
Q4 		$4.54M Buy
36,566
+779
+2% +$86.4K ﹤0.01% 1657
2023
Q3 		$4.15M Buy
35,787
+13,423
+60% +$1.64M ﹤0.01% 1542
2023
Q2 		$2.63M Sell
22,364
-28,221
-56% -$2.88M ﹤0.01% 1964
2023
Q1 		$4.05M Buy
50,585
+21,825
+76% +$1.71M ﹤0.01% 1611
2022
Q4 		$2.28M Sell
28,760
-21,063
-42% -$1.56M ﹤0.01% 1934
2022
Q3 		$3.47M Buy
49,823
+12,806
+35% +$925K ﹤0.01% 1766
2022
Q2 		$2.43M Buy
37,017
+21,785
+143% +$1.36M ﹤0.01% 1986
2022
Q1 		$1.01M Sell
15,232
-19,656
-56% -$1.23M ﹤0.01% 2937
2021
Q4 		$2.44M Buy
34,888
+4,926
+16% +$287K ﹤0.01% 2449
2021
Q3 		$1.56M Sell
29,962
-19,413
-39% -$1.15M ﹤0.01% 2735
2021
Q2 		$3.36M Buy
49,375
+10,456
+27% +$730K ﹤0.01% 2258
2021
Q1 		$3M Buy
38,919
+17,244
+80% +$1.25M ﹤0.01% 2205
2020
Q4 		$1.3M Buy
21,675
+19,943
+1,151% +$996K ﹤0.01% 3275
2020
Q3 		$75K Sell
1,732
-32,489
-95% -$1.41M ﹤0.01% 5323
2020
Q2 		$1.42M Sell
34,221
-25,488
-43% -$1.23M ﹤0.01% 3181
2020
Q1 		$2.58M Sell
59,709
-1,060
-2% -$55.4K ﹤0.01% 2248
2019
Q4 		$3.37M Buy
60,769
+46,937
+339% +$2.3M ﹤0.01% 2402
2019
Q3 		$481K Buy
13,832
+11,377
+463% +$509K ﹤0.01% 4369
2019
Q2 		$99K Sell
2,455
-19,659
-89% -$643K ﹤0.01% 5881
2019
Q1 		$728K Buy
22,114
+11,811
+115% +$278K ﹤0.01% 3750
2018
Q4 		$214K Buy
+10,303
New +$216K ﹤0.01% 4959

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup's KRYS Position: Q1 2026 in Review

Citigroup increased its Krystal Biotech (KRYS) stake by 4.1% in Q1 2026, buying an estimated $327K and bringing the position to 31,172 shares worth $8.05M. The position accounts for ﹤0.01% of the portfolio, ranked #1607.

Citigroup first reported a position in KRYS in Q4 2018 and has held it in 30 quarters since. The position peaked at $15.6M in Q4 2024. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Citigroup held 31,172 shares of Krystal Biotech worth $8.05M as of Q1 2026.
  • Citigroup bought 1,229 Krystal Biotech shares in Q1 2026, an estimated $327K.
  • Krystal Biotech made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #1607 holding.
  • Citigroup first reported a position in Krystal Biotech in Q4 2018 and has held it in 30 quarters since.
  • Citigroup's Krystal Biotech position peaked at $15.6M in Q4 2024.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.